Renasant Bio

The company's scientific foundation was established by University of California, San Francisco professors Jeremy Reiter and Markus Delling, whose research into ADPKD's biology formed the basis of the company's approach. They initiated contact with 5AM Ventures in 2022, leading to the company's incubation within 5AM's 4:59 Initiative. Renasant Bio is headquartered in Berkeley, California. The company is led by CEO Emily Conley, a scientist who previously served as CEO of Federation Bio and worked in business development at 23AndMe. The scientific team includes Chief Scientific Officer Gus Gustafson, a veteran of Johnson & Johnson and Merck & Co.

Renasant Bio's business model is centered on the research and development of a pipeline of pharmaceutical products. Its primary market is patients suffering from ADPKD, a global issue affecting an estimated 12 million people. The company's revenue generation will depend on the successful clinical development and commercialization of its therapeutic candidates. The recent seed funding is allocated to advancing its lead drug programs through preclinical and into clinical testing over the next few years. The company's approach is inspired by treatments for cystic fibrosis, focusing on correcting and potentiating the function of proteins that are malformed due to genetic mutations.

The company is developing a pipeline of oral small molecule therapies, specifically "corrector" and "potentiator" programs. The lead candidate is a small molecule corrector in preclinical testing, designed to help misfolded polycystin proteins (PC1 and PC2) fold properly, thereby restoring their normal function across a wide range of ADPKD-causing mutations. This is intended to work as a standalone treatment. Additionally, Renasant is developing a first-in-class potentiator therapy to enhance ion flux through the polycystin channel, which could be used in tandem with the corrector to prevent the formation or growth of kidney cysts. The company has developed proprietary assays to assess protein trafficking and other key mechanisms to guide the development of these novel therapies.